PAPatrik Andersson

Patrik Andersson

*This is an algorithmically generated author record based on publicly available information.

Patrik Andersson has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    MRI-derived body composition in bipolar and psychotic disorders

    by Daniel Edvard Askeland-Gjerde, Lars T. Westlye, Dag Alnaes, Patrik J. Andersson, Dani Beck, Ingrid Torp Johansen, Jennifer Linge, Geneviève Richard, Henning S. Rise, Paul M. Thompson, et al.

    Objective: Bipolar (BD) and psychotic disorders (PD) are severe mental disorders (SMDs) associated with higher cardiometabolic disease burden. Prior studies of body composition in SMDs are inconclusive. Magnetic resonance imaging (MRI) offers detailed insights into body composition and may improve our understanding of cardiometabolic disease risk in patients with SMDs. Methods: We derived body composition measures from MRI of patients with BD (n=36, 63.9% females, mean age=36.6±10.9 years), PD (n=27, 33.3% females, mean age=31.7±8.9 years), and controls (n=251, 78.8% females, mean age=40.7±12.1 years). Using linear models we tested for case-control differences in body mass index (BMI) and body composition in all patients and split by diagnostic group (BD and PD), accounting for age, sex, and scanner, and subsequently adding BMI. Next, we tested for age- and sex-adjusted associations between body composition and antipsychotic dose in patients. Results: Analyses showed significantly higher BMI (BD: Cohen’s d=0.70; PD: d=0.65), abdominal subcutaneous fat (BD: d=0.78; PD: d=0.71), visceral fat (BD: d=0.76; PD=0.68), liver fat (BD: d=0.53; PD: n.s.), and thigh muscle fat infiltration (BD: d=0.80; PD: d=0.87) in cases compared to controls. When accounting for BMI, muscle fat infiltration remained significantly higher (BD: d=0.54; PD: d=0.68) and thigh muscle volume was lower (BD: d=-0.65; PD: d=-0.63). There were no significant associations of antipsychotic dose with BMI or body composition. Conclusions: The observed case-control differences suggest that individuals with BD and PD, at the group level, exhibit higher regional fat accumulation and lower muscle volume, possibly contributing to the heightened risk for cardiometabolic comorbidity in SMDs.

  • Poor muscle health and cardiometabolic risks associated with antidepressant treatment

    by Patrik Andersson, Jennifer Linge, Tiril P. Gurholt, Ida E. Sønderby, Guy Hindley, Ole A. Andreassen, Olof Dahlqvist Leinhard

    Objective: This study aims to investigate whether antidepressant users display differences in fat distribution and muscle composition relative to non‐users and to explore risk factors for developing cardiovascular disease (CVD) and type 2 diabetes.Methods: The study used quantitative adipose and muscle tissue measures derived from magnetic resonance imaging data from UK Biobank (N = 40,174). Fat distribution and muscle composition of selective serotonin reuptake inhibitor (SSRI) and tricyclic antidepressant (TCA) users were compared with sex‐, age‐, and BMI‐matched control individuals. Cox regression models were used to test for increased risk of developing CVD and type 2 diabetes.Results: SSRI users had more visceral fat, smaller muscle volume, and higher muscle fat infiltration compared with matched control individuals. Female users showed a larger increase in BMI over time compared with male users. However, male users displayed an unhealthier body composition profile. Male SSRI users also had an increased risk of developing CVD. Both male and female TCA users showed lower muscle volume and an increased risk of developing type 2 diabetes.Conclusions: Adverse changes in body composition of antidepressant users are not captured by tracking the body weight or the BMI of the patients. These changes may lead to a worsened cardiometabolic risk profile.


  • Open Access

    Effects of COVID-19 on the Human Central Olfactory System: A Natural Pre-Post Experiment

    by E. Thunell, M.G. Peter, V. Lenoir, P. Andersson, B.N. Landis, M. Becker, J.N. Lundström

    BACKGROUND AND PURPOSE: Reduced olfactory function is the symptom with the highest prevalence in coronavirus disease 2019 (COVID-19) with nearly 70% of infected individuals experiencing partial or total loss of their sense of smell at some point during the disease. The exact cause is not known, but beyond peripheral damage, studies have demonstrated insults to both the olfactory bulb and central olfactory brain areas. However, these studies often lack both baseline pre-COVID-19 assessments and control groups, and the effects could, therefore, simply reflect pre-existing risk factors. MATERIALS AND METHODS: Shortly before the COVID-19 outbreak, we completed an olfactory-focused study, which included structural MR brain images and a full clinical olfactory test. Opportunistically, we invited participants back 1 year later, including 9 participants who had experienced mild-to-moderate COVID-19 (C19+) and 12 who had not (C19−), creating a natural pre-post experiment with a control group. RESULTS: Despite C19+ participants reporting subjective olfactory dysfunction, few showed signs of objectively altered function. Critically, all except 1 individual in the C19+ group had reduced olfactory bulb volume (average reduction, 14.3%), but this did not amount to a significant statistical difference compared with the control group (2.3%) using inference statistics. We found no morphologic differences in olfactory brain areas but stronger functional connectivity between olfactory brain areas in the C19+ group at the postmeasure. CONCLUSIONS: Our data suggest that COVID-19 might cause long-term reduction in olfactory bulb volume and altered functional connectivity but with no discernible morphologic differences in cerebral olfactory regions.


  • Decoding stimulus identity in occipital, parietal and inferotemporal cortices during visual mental imagery

    by Flavio Ragni, Raffaele Tucciarelli, Patrik Andersson, Angelika Lingnau